Study of Growth Factor Receptors in Pulmonary Hypertension Related to Systemic Sclerosis
Author Information
Author(s): Overbeek Maria J, Boonstra Anco, Voskuyl Alexandre E, Vonk Madelon C, Vonk-Noordegraaf Anton, van Berkel Maria PA, Mooi Wolter J, Dijkmans Ben AC, Hondema Laurens S, Smit Egbert F, Grünberg Katrien
Primary Institution: VU University Medical Center
Hypothesis
The study aims to explore the role of PDGFR-β and EGFR in the pulmonary vasculature of patients with systemic sclerosis-associated pulmonary arterial hypertension (SScPAH) compared to idiopathic pulmonary arterial hypertension (IPAH) and pulmonary veno-occlusive disease (PVOD).
Conclusion
PDGFR-β immunoreactivity is more common and intense in small vessels of SScPAH compared to IPAH, indicating its potential role in the disease's vascular remodeling.
Supporting Evidence
- All SScPAH cases showed PDGFR-β immunoreactivity in small vessels.
- Intensity of PDGFR-β immunoreactivity was stronger in SScPAH than in IPAH.
- Three of nine IPAH cases showed PDGFR-β immunoreactivity in small vessels.
- PDGFR-β immunoreactivity patterns did not differ between SScPAH and PVOD.
Takeaway
This study looked at how certain proteins behave in the lungs of patients with a specific type of high blood pressure caused by a disease called systemic sclerosis. They found that one protein was more active in these patients than in others.
Methodology
Lung tissue specimens from patients with SScPAH, IPAH, PVOD, and controls were examined for immunoreactivity of PDGFR-β and EGFR using immunohistochemistry.
Potential Biases
Potential biases may arise from using archival tissue from different laboratories, which could affect the quality of immunoreactivity.
Limitations
The study's small sample size limits the generalizability of the findings.
Participant Demographics
The study included 5 SScPAH, 9 IPAH, 6 PVOD patients, and 5 controls, with a median age range of 32 to 60 years.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website